Cyclooxygenase-2 expression and recurrence of colorectal adenomas: Effect of aspirin chemoprevention

Gut

Volumn 59, Issue 5, 2010, Pages 622-629

  Benamouzig, Robert ^a   Uzzan, Bernard ^a   Martin, Antoine ^a   Deyra, Jacques ^b   Little, Julian ^b   Girard, Bernard ^b   Chaussade, Stanislas ^c  

^a AVICENNE HOSPITAL   (France)

^b APACC Study Group

^c université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIN D1; CYCLOOXYGENASE 2; K RAS PROTEIN; LYSINE ACETYLSALICYLATE; PLACEBO; PROTEIN P53;

ADULT; ARTICLE; CANCER GRADING; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSPLASIA; EPITHELIUM; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STROMA;

ADENOMA; ADOLESCENT; ADULT; AGED; ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77951737376     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.175406     Document Type: Article

References (71)

1. Flossmann E, Rothwell PM. on behalf of the British Doctors Aspirin Trial and the UKTIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-1613
2. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-923 (Pubitemid 41215460)
3. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008;134:21-28 (Pubitemid 350309311)
4. Stürmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998;128:713-720 (Pubitemid 28204862)
5. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. (Pubitemid 41002838)
6. Dubé C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US preventive services task force. Ann Intern Med 2007;146:365-375 (Pubitemid 351650597)
7. Baron JA. Intermediate effect markers for colorectal cancer. IARC Sci Publ 2001;154:113-129
8. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899 (Pubitemid 36297997)
9. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38. (Pubitemid 350309319)
10. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. Erratum in N Engl J Med 2003;348:1939.
11. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-336 (Pubitemid 36929412)
12. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-266
13. Kargman S, Wong E, Greig GM, et al. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol 1996;52:1113-1125 (Pubitemid 26338270)
14. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188 (Pubitemid 24294584)
15. Gustafson-Svärd C, Lilja I, Hallböök O, et al. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996;38:79-84. (Pubitemid 26020933)
16. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-4826 (Pubitemid 28503676)
17. Sinicrope FA, Lemoine M, Xi L, et al. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999;117:350-358 (Pubitemid 29352943)
18. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-1257 (Pubitemid 29468497)
19. Dimberg J, Samuelsson A, Hugander A, et al. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999;45:730-732 (Pubitemid 29492147)
20. Masunaga R, Kohno H, Dhar DK, et al. Cycooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-4068
21. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-328 (Pubitemid 30453571)
22. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-1347 (Pubitemid 33140451)
23. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-1041 (Pubitemid 34408266)
24. Yamauchi T, Watanabe M, Kubota T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98-103. (Pubitemid 34072758)
25. Petersen S, Haroske G, Hellmich G, et al. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002;22:1225-1230 (Pubitemid 34836179)
26. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31:147-154 (Pubitemid 36330117)
27. Konno H, Baba M, Shoji T, et al. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002;19:527-534 (Pubitemid 35178671)
28. Wu AW, Gu J, Ji JF, et al. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003;9:1990-1994 (Pubitemid 37168428)
29. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471 (Pubitemid 40053411)
30. Adegboyega PA, Ololade O, Saada J, et al. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 2004;10:5870-5879 (Pubitemid 39180968)
31. Kawasaki T, Nosho K, Ohnishi M, et al. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008;8:33. (Pubitemid 351325426)
32. Bamba H, Ota S, Kato A, et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999;83:470-475 (Pubitemid 29489860)
33. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545-553 (Pubitemid 30643810)
34. Fujita M, Fukui H, Kusaka T, et al. Relationship between cyclooxygenase-2 expression and K-ras gene mutation in colorectal adenomas. J Gastroenterol Hepatol 2000;15:1277-1281
35. Arao J, Sano Y, Fujii T, et al. Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum. Dis Colon Rectum 2001;44:1319-1323 (Pubitemid 32845911)
36. Sonoshita M, Takaku K, Oshima M, et al. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002;62:6846-6849 (Pubitemid 35424071)
37. Elder DJ, Baker JA, Banu NA, et al. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 2002;198:428-434 (Pubitemid 35446995)
38. Einspahr JG, Krouse RS, Yochim JM, et al. Association between cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res 2003;63:3891-3893 (Pubitemid 36917900)
39. Sheehan KM, O'Connell F, O'Grady A, et al. The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas. Eur J Gastroenterol Hepatol 2004;16:619-625 (Pubitemid 38703872)
40. Tatsu K, Hayashi S, Shimada I, et al. Cyclooxygenase-2 in sporadic colorectal polyps: immunohistochemical study and its importance in the early stages of colorectal tumorigenesis. Pathol Res Pract 2005;201:427-433 (Pubitemid 41093720)
41. Pisano C, Ottaiano A, Tatangelo F, et al. Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas. Anticancer Res 2005;25:2065-2068 (Pubitemid 40904605)
42. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059 (Pubitemid 34984619)
43. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952 (Pubitemid 30419089)
44. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895 (Pubitemid 44315981)
45. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-1682 (Pubitemid 44958508)
46. Bertagnolli M, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884 (Pubitemid 44315980)
47. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142 (Pubitemid 47010839)
48. Voutsadakis IA. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 2007;11:252-285
49. Benamouzig R, Yoon H, Little J, et al. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. Eur J Cancer Prev 2001;10:327-335 (Pubitemid 32735349)
50. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-2855 (Pubitemid 46179475)
51. DuBois RN, Radhika A, Reddy BS, et al. Increased cyclooxygenase-2 levels in carcinogen-induced colonic tumors. Gastroenterology 1996;110:1259-1262 (Pubitemid 26113767)
52. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134-1140 (Pubitemid 26327618)
53. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044
54. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-2560 (Pubitemid 26171681)
55. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996;87:803-809 (Pubitemid 26404280)
56. -/- mice. Gastroenterology 2000;118:337-345
57. Sheehan KM, Steele C, Sheahan K, et al. Association between cyclooxygenase-2-expressing macrophages, ulceration and microvessel density in colorectal cancer. Histopathology 2005;46:287-295 (Pubitemid 40343175)
58. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, et al. PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 2006;132:76-84. (Pubitemid 41752048)
59. Konstantinopoulos PA, Vandoros GP, Karamouzis MV, et al. EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Cell Oncol 2007;29:477-482
60. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110: 669-674 (Pubitemid 26071834)
61. Ajiki T, Fujimori T, Ikehara H, et al. K-ras gene mutation related to histological atypias in human colorectal adenomas. Biotech Histochem 1995;70:90-94
62. Maltzman T, Knoll K, Martinez ME, et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 2001;121:302-309 (Pubitemid 32729377)
63. Sheng H, Shao J, Dubois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 2001;61:2670-2675 (Pubitemid 32691132)
64. Robertson DJ, Burke CA, Welch HG, et al. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med 2009;151:103-109
65. Shao J, Sheng H, Inoue H, et al. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000;275:33951-33956
66. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-245 (Pubitemid 26233752)
67. Yu HG, Huang JA, Yang YN, et al. The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 2002;32:838-846
68. Lai MY, Huang JA, Liang ZH, et al. Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol 2008;14:4227-4233
69. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-959 (Pubitemid 2115182)
70. Schwenger P, Bellosta P, Vietor I, et al. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci U S A 1997;94:2869-2873 (Pubitemid 27157231)
71. Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-7864